Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 19, 2026.

New Insights Into the Role and Mechanism of Partial Epithelial-Mesenchymal Transition in Kidney Fibrosis

Lili Sheng, Shougang Zhuang

Frontiers in Physiology · 2020 · Review · CC BY

doi:10.3389/fphys.2020.569322

Abstract

Epithelial-mesenchymal transition (EMT) is described as the process in which injured renal tubular epithelial cells undergo a phenotype change, acquiring mesenchymal characteristics and morphing into fibroblasts. Initially, it was widely thought of as a critical mechanism of fibrogenesis underlying chronic kidney disease. However, evidence that renal tubular epithelial cells can cross the basement membrane and become fibroblasts in the renal interstitium is rare, leading to debate about the existence of EMT. Recent research has demonstrated that after injury, renal tubular epithelial cells acquire mesenchymal characteristics and the ability to produce a variety of profibrotic factors and cytokines, but remain attached to the basement membrane. On this basis, a new concept of "partial epithelial-mesenchymal transition (pEMT)" was proposed to explain the contribution of renal epithelial cells to renal fibrogenesis. In this review, we discuss the concept of pEMT and the most recent findings related to this process, including cell cycle arrest, metabolic alternation of epithelial cells, infiltration of immune cells, epigenetic regulation as well as the novel signaling pathways that mediate this disturbed epithelial-mesenchymal communication. A deeper understanding of the role and the mechanism of pEMT may help in developing novel therapies to prevent and halt fibrosis in kidney disease.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

The progress of renal fibrosis – glomerulosclerosis and tubulointerstitial fibrosis – is characterized by an excessive deposition of extracellular matrix (ECM) components in the tubular interstitium. Fibrosis in the short term is an adaptive mechanism for repairing tissue damage, whereas persistent fibrosis after severe or repetitive injury eventually leads to renal failure as functional renal parenchyma is replaced by connective tissue. Up to now, there is no specific therapy to halt progression of renal fibrosis. Moreover, the cellular and molecular mechanisms mediating fibrosis are still not well understood. A better understanding of the complex mechanisms and related cellular mediators of kidney fibrosis is urgently needed to develop new therapeutic approaches to prevent chronic kidney disease.

During the pathogenesis of renal fibrosis, activated fibroblasts or myofibroblasts are generally thought of as the major type of matrix-producing cells. Similar to smooth muscle cells, myofibroblasts express α-SMA and secrete a pericellular matrix containing collagen and glycosaminoglycans. The origin of myofibroblasts in the kidney remains uncertain, but is considered to be derived from various sources: proliferation of resident fibroblasts, differentiation from local fibroblasts or pericytes, direct and complete transition from resident endothelial or epithelial cells through endothelial-mesenchymal transition (EndoMT) and epithelial-mesenchymal transition (EMT). Some studies have suggested that bone marrow derived fibroblasts also contribute to the myofibroblast population. One of major controversies over renal interstitial fibrosis revolves around the relative contribution of activated tubular epithelial cells to the total myofibroblast pool.

EMT of tubular epithelial cells has been long considered a mechanism that promotes renal fibrosis. During that process, injured epithelial cells are activated and undergo a phenotypic conversion, acquiring the features of matrix-producing fibroblasts or myofibroblasts. EMT was primarily identified in the kidney in a landmark article published in 1994 in which cells in renal interstitium with immunohistochemical features of tubular cells were found in end-stage kidney disease. In all tissues including kidney, key events during the process of EMT are summarized as follows: (1) dissolution of epithelial cell junctions and loss of cell polarity; (2) downregulation of epithelial proteins expression such as E-cadherin, zonula occludens-1 (ZO-1), and upregulation of mesenchymal marker expression including α-smooth muscle actin (α-SMA), vimentin, fibroblast-specific protein-1 (FSP1), and fibronectin; (3) reorganization of the cytoskeletal architecture and changes in cellular morphology with increased cell protrusions and motility; (4) acquisition of the ability to secrete factors to degrade extracellular matrix and exhibit invasive behavior. Most studies applied co-immunostaining for markers of epithelial cells and, fibroblasts to detect the alternation of EMT transcriptional program. This does not, however, provide direct evidence of EMT. Moreover, the exact percentage of fibroblasts that derive from tubular epithelial cells in a diseased kidney is entirely uncertain and remains under debate.

The controversy over the relative contribution of EMT to the total fibroblast or myofibroblast pool lasted many years. A study in 2013 used multiple genetically engineered mice to track the source of myofibroblasts. It was found that the source of myofibroblasts is split, with 50% arising from proliferation of local resident fibroblasts, 35% through differentiation from bone marrow, 10% from endothelial-to-mesenchymal transition. The contribution of EMT only occupies 5% of the total myofibroblast pool. Although a complete phenotype alternation from renal tubular epithelial cell to myofibroblast is rare, most studies provide evidence for a large population of tubular epithelial cells that co-express epithelial and mesenchymal markers. Recent studies found that the dedifferentiated TECs remain attached to the basement membrane after renal injury. This type of renal epithelial cells is considered to have undergone partial EMT. In this review article, we will discuss advances in our understanding of the role and mechanism of partial EMT in kidney fibrosis.

Identification of Partial Epithelial-Mesenchymal Transition in the Kidney

In an early review examining the EMT hypothesis, it was suggested that epithelial cells undergo a “partial EMT” to acquire some of the phenotypic characteristics fibroblasts rather than converting to a “fully fibroblastic phenotype”. In 2015, two studies offered new perspective into the potential role of partial EMT in the development and progression of renal fibrosis. Both studies demonstrated that during the process of fibrosis, TECs expressed both markers of epithelial and mesenchymal cells while remaining attached to the basement membrane during fibrosis. demonstrated that Snail1 induced partial EMT of renal tubular cells, which produces fibrogenic cytokines to promote myofibroblasts proliferation and macrophage recruitment. showed that the partial EMT program is associated with p21-mediated G2/M cell cycle arrest in proximal TECs. And inhibition of the EMT program by conditional deletion of Twist1 or Snai1 resulted in the maintenance of TEC integrity, decrease of immune cell infiltration and attenuation of interstitial fibrosis. These two observations demonstrated that without a complete conversion to fibroblast, a partial EMT is enough to induce TEC dysfunction by triggering cell cycle arrest, thereby promoting the secretion of profibrogenic cytokines and fibrosis.

Phenotypic Alterations of Renal Tubular Cells With Partial EMT

During the process of partial EMT in kidney, epithelial cells experience series of changes, including cell-cycle arrest, metabolic alternation, and inflammation, that result in disturbed epithelial-mesenchymal crosstalk, leading to renal fibrosis.

Cell-Cycle Arrest – Defective Repair and Regeneration

The cell cycle consists of four phases (G1, S, G2, M), each of which has specific characteristics. Cell division starts with the G1 phase. In the G2 phase, the cell prepares itself for mitosis by genetic material replication and protein synthesis. Genetic material and cellular components are distributed to two daughter cells during the M phase. In G2/M arrest, cells are blocked from entering mitosis unless DNA replication or repair is complete, a cell size is large enough to divide and the cell has enough energy.

In acute kidney injury (AKI) models, such as ischemic reperfusion, acid toxic nephropathy, and obstructive mouse models, proximal TECs usually undergo G2/M phase cell-cycle arrest. Chronic kidney disease is also associated with inappropriate cell cycle progression in TECs. The number of tubular cells that undergo G2/M arrest is correlated with the degree of fibrosis. Proximal tubular cells in G2/M arrest activate c-jun NH2-terminal kinase (JNK) signaling and upregulate profibrotic cytokine generation. The cells at G2/M phase have higher levels of COL4A1, ACTA2, TGF-β1, and CTGF expression. Activation of signaling pathways such as TGF-β1 also triggers epithelial arrest at the G2/M phase of the cell cycle. Reversal of G2/M arrest rescues cells from the fibrogenic effects. This observation was further confirmed by several other groups. In the setting of EMT, showed that after a fibrotic injury, TECs undergo a pEMT program and G2/M cell cycle arrest, which impairs cell regeneration and halts tissue repair, resulting in chronic fibrosis. Inhibition of pEMT in TECs protects kidney function by promoting cell cycle-dependent repair of the injured kidney. Therapeutic strategies targeting the G2/M check point are thought to be quite promising. Canaud and Bonventre suggested several approaches targeting cell cycle arrest. These include prevention of cells from activating downstream checks that trigger G2/M arrest, helping cells overcome G2/M checkpoints, facilitating apoptosis or selective depletion of senescent cells, and blocking pathways that are involved in production of profibrotic cytokines.

Metabolic Alternation

The renal tubular epithelial cell is one of the most metabolically active cells in the body, and investigators are increasingly looking into the metabolic changes that occur during kidney fibrosis. Injured epithelial cells display dramatic metabolic rearrangements that affect their capacity to regenerate and influence fibrogenesis. Tubular cells have a high energy demand, producing ATP mostly by fatty acid oxidation (FAO). However, fibrotic kidneys exhibit lower expression of key regulators of FAO and higher intracellular lipid deposition in human and mouse models. Dysregulated FAO results in intracellular lipid accumulation and, inflammatory cell infiltration and cytokine secretion, and acceleration of interstitial fibrosis. Lipid accumulation also promoted glucose-induced morphological changes of tubular epithelial cell, as well as the cytoskeletal switch including loss of E-cadherin and acquisition of α-SMA. These results suggest that the decrease of FAO along with accumulation of lipids may promote development of EMT.

Currently, there is still no direct evidence indicating that the EMT results in metabolic alterations in the kidney. Nevertheless, demonstrated that TGF-β1 can induce remarkable depression of FAO through Smad3-mediated repression of the expression of PPARGC1a, one of the key FAO transcription factors in fibrotic kidneys. Given that TGFβ1-induced activation of Smad3 is also a key signaling event leading to EMT, this study also suggests that FAO depression may occur secondary or in parallel to EMT. Supporting this, it has been reported that upregulation of Snail, a major regulator of EMT, correlated with the downregulation of critical genes involved in FAO expression in hepatocellular carcinomas; pharmacological inhibition of FAO reverses Snail-mediated metabolic reprogramming in vivo and progression of breast cancer. Future studies are needed to elucidate the role of EMT in the regulation of FAO or other metabolic alteration in the kidney after fibrotic injuries.

Pathological Secretome

Inflammation is widely described as a key promotor of kidney fibrosis. It is initiated as a protective response to acute injury. But when it persists, inflammation may contribute to fibrotic progression. Tubulointerstitial inflammation is observed in the early stage of different renal diseases. Apart from inflammatory cell infiltration, damaged TECs can be transformed into a secretory phenotype and act as proinflammatory mediators. The inflammatory response of TECs to injury is likely to be a key determinant in the development of interstitial fibrosis.

An early study explored the interactions between activated proximal tubular cells expressing the myofibroblast markers and peritubular cells, especially inflammatory cells. In remnant kidney models, α-SMA expression became evident in tubular epithelial cells at day 30, correlating with the ED1+ macrophages co-localization in peritubular areas in kidneys. This result suggests a relation between phenotype transition of epithelial cells and inflammatory cell recruitment. and, examined the relationship between inflammation and EMT. They found that in fibrotic kidney, the immune response was attenuated after EMT inhibition with downregulated inflammatory cytokines. Lovisa et al. found that EMT inhibition resulted in a distinct reduction in immune cell infiltration in renal interstitium such as CD3+ T cells, CD8+ T cells, CD11c+ dendritic cells and macrophages. also observed a reduction in the presence of F4/80 macrophages, as well as lower levels of pNF-κB, cytokines and chemokines in tubular cells after EMT inhibition by deletion of Snail. In particular, the levels of M2-type macrophages, which are thought to be pro-fibrogenic during tissue repair, decreased evidently. Taken together, this suggests that blocking EMT could halt the related secretome of TECs and inhibit subsequent inflammation, serving as a potential approach to reduce fibrosis.

Contribution of pEMT to Renal Fibrosis

Tubulointerstitial fibrosis is commonly seen during CKD progression. Studies showed that the phenotypic changes suggesting EMT correlate with the progression of kidney fibrosis. One study enrolled 83 kidney transplant recipients who had undergone allograft biopsies at 3 and 12 months after transplantation. Patients with vimentin and β-catenin expression in more than 10% of tubules at 3 months had much more severe interstitial fibrosis at 1 year. In addition, the presence of early phenotypic changes in TECs was associated with poorer graft function 18 month after transplantation. These data suggest that epithelial phenotypic changes represent an “activated state” of the tubular cells that can lead to fibrosis.

The fibrotic interstitium is characterized by fibroblast and myofibroblast proliferation, inflammatory cell infiltration and tubular cell atrophy, as well as excessive accumulation of ECM. Historical data suggest that the progression of renal fibrosis might be the result of an altered epithelial-mesenchymal cellular crosstalk. Well-balanced crosstalk between tubular epithelial cells and mesenchymal cells or inflammatory cells is essential to maintain a normal and healthy tubulointerstitium.

Experiments in the early 1990s showed the role of disturbed crosstalk between different cells during fibrogenesis. In the study of, cultured proximal tubule cells were found to be capable of stimulating fibroblast proliferation, collagen synthesis and MMP activity. This may occur through paracrine mechanisms that involve TEC-derived growth factors such as PDGF and TGF-β1. In cultured kidney epithelial cells, TGF-β1 stimulated profibrotic cytokines production and then promoted the proliferation and transition of pericytes to myofibroblasts. showed that activation of the Notch1 pathway in TECs contributes to tubulointerstitial fibrogenesis. TGF-β1 treated TECs induced Notch1 pathway activation, which not only promoted epithelial dysfunction, but also stimulated interstitial cell proliferation including myofibroblast proliferation. These results provide compelling evidence that TECs could regulate the behavior of neighboring myofibroblasts and fibroblasts in the interstitium. Disturbance of normal epithelial-mesenchymal unit crosstalk may be an initial cause of fibroblast and myofibroblast activation in the course of renal fibrosis.

showed that after partial EMT program activation, tubular epithelial cells were still integrated in the tubules and could express epithelial-related genes. The incomplete EMT program was still able to promote proliferation and activation of interstitial fibroblasts. This suggests that tubular cells undergoing partial EMT may produce some profibrotic cytokines/growth factors to induce renal fibroblast activation. In this regard, it has been reported that TGF-β1 treatment can induce cultured kidney epithelial cells to express several profibritic cytokines that stimulate the proliferation and transition of pericytes to myofibroblasts. Therefore, the fibrogenic response of EMT activation may not need complete transition of epithelial cells into myofibroblasts, and the cell with partial EMT acquire the ability to produce profibrotic cytokines/growth factors to induce renal fibroblast activation and renal fibrosis.

Increasing evidence indicates that the occurrence of EMT in renal tubular cells is associated with cellular senescence. Cellular senescence is mainly characterized by growth arrest and formation of a senescence-associated secretory phenotype that produces numerous profibrotic cytokines/growth factors, including TGF-β1. As mentioned, some growth factors and TGF-β1 not only induce renal fibroblast activation, but also stimulate the EMT response. Thus the cellular senescence-initiated EMT program may contribute to renal fibrosis. On the other hand, TGF-β1-induced partial EMT can also promote renal epithelial cells arrest at the G2/M phase of cell cycle and parenchymal damage in renal fibrosis. Therefore, it seems that EMT and senescence of renal tubular cells are intrinsically linked, leading to a vicious cycle in promoting chronic fibrosis. Currently, a causative link between these two processes and molecular mechanisms related to their reciprocal regulation in the fibrotic kidney are not yet been fully understood. It has been reported that induction of Twist or Snai1 expression in renal epithelial cells is sufficient to induce EMT and promote prolonged TGF-β1–induced cell cycle arrest in G2/M phase, suggesting that activation of these two transcriptional factors may play an essential role in mediating these two processes. Further studies are required to identify the signaling pathways that regulate senescence and EMT cross-talk as well as their potential co-targets.

New Signals That Mediate pEMT and Subsequent Renal Fibroblast Activation

Defective crosstalk between epithelial cell and mesenchymal cell might involve multiple pathways of injury and repair. Epithelial cells communicate with interstitial fibroblasts by promoting activation and excitation of growth factors, such as TGF-β, CTGF, EGF, and FGF. In injured tubular epithelial cells, regular signaling pathways are disrupted and irregular pathways, such as Wnts and sonic hedgehog (SHH), are activated. Activation of these irregular pathways could produce ligands of developmental pathways in pericytes or fibroblasts and trigger cell proliferation and fibrosis.

Sonic Hedgehog (SHH) Signaling

Sonic hedgehog (SHH) signaling plays an important role in embryonic development, tissue regeneration and organogenesis. The disturbed activation of this pathway leads to pathological consequences, including the development of types of human tumors and fibrogenesis.

SHH expression is extremely low and difficult to detect in healthy kidney. It was activated in renal tubular epithelial cells in models of renal mass ablation, ischemia/reperfusion injury (IRI), and in renal tubules of biopsy specimens of CKD patients. When activated, it was predominantly localized in renal tubular epithelial cells. The sonic hedgehog pathway transcriptional effectors GLI1 and GLI2 are expressed in myofibroblast progenitors. identified interstitial fibroblasts to be the targets of renal SHH signaling. Incubation with SHH or SHH overexpression promoted kidney fibroblast proliferation and stimulated expression of numerous proliferation-related genes. One study also found that in ureteral obstruction model, SHH localized predominantly to the renal tubular epithelium. After administration of recombinant SHH protein, renal interstitial fibroblasts showed increased α-SMA, desmin, fibronectin, and collagen I expression, suggesting that SHH signaling participates in promoting myofibroblast activation and extracellular matrix accumulation.

SHH signaling might be involved in the process of EMT. Experiments demonstrated that injuries activated hedgehog signaling, resulting in tubular EMT and ECM production. Bai found that after ureteral obstruction, epithelial cells undergo G2/M cell cycle arrest and acquire a myofibroblastic phenotype. Meanwhile, the injury also stimulated activation of SHH signaling pathway. SHH-treated renal fibroblasts exhibited a fibrogenic response. Blockade of SHH inhibited fibroblast activation and improved ECM deposition. These results suggest that tubule-derived SHH activation might target interstitial fibroblasts and mediate epithelial-mesenchymal communication during EMT, thus promoting interstitial fibroblast proliferation and activation. SHH inhibition may be a potential therapeutic strategy to reduce fibroblast activation during kidney fibrosis.

Wnt/β-Catenin Signaling

The Wnt family is a group of lipid-modified glycoproteins. The most studied Wnt signaling pathway in kidney is the Wnt/β-catenin signaling pathway, which plays an essential role in regulating nephrogenesis and pathogenesis of kidney diseases.

Studies have shown a renoprotective effect of wnt/β-catenin in AKI models after either ischemic or nephrotoxic insults. Wnt/β-catenin protein was predominantly expressed in the kidney tubular epithelium. Tubule specific ablation of β-catenin aggravates injuries. Nevertheless, chronic and persistent activation of this signaling pathway could lead to development and progression of CKD. found that Wnt/β-catenin activation in UUO mice was associated with MMP-7, fibronectin, Twist, and c-Myc expression. investigated the role of Wnt/β-catenin activation in IRI models. Moderate IRI led to acute kidney injury and transient Wnt/β-catenin activation, as a result, normal kidney morphology and function were restored. Severe IRI accompanied sustained and exaggerated Wnt/β-catenin activation resulted in the development of renal fibrotic lesions, suggesting that persistent Wnt/β-catenin signaling activation promoted fibroblast proliferation and renal fibrosis. Epithelium-derived Wnt/β-catenin signaling might disturb normal epithelial-mesenchymal crosstalk and thereby promote fibrosis.

Recent evidence has demonstrated Wnt/β-catenin also contributes to the EMT process in tubular cells. Hydrogen sulfide inhibits TGF-β1-induced EMT via Wnt/β-catenin pathway. CTGF induces tubular EMT through the activation of canonical Wnt signaling. Chronic cadmium exposure induces activation of the Wnt pathway and upregulation of EMT markers in mouse kidney. It is indicated that Wnt/β-catenin signaling was activated during EMT process, and might alter the regular epithelial-mesenchymal cellular crosstalk.

Epigenetic Regulation of pEMT in the Kidney

Epigenetic modification refers to stable heritable changes in gene expression without changes in DNA sequence. It is thought to contribute to the regulation of gene expression under different conditions. The chromatin consists of histone proteins and the DNA wrapped around them. Epigenetic modifications involve selective unwinding of the double helix and exposure of the underlying genetic material. The modifications are well-balanced in normal cells. Small changes may lead to major consequences and result in cellular dysfunction or malignant outgrowth. Growing evidence suggests the epigenetic regulation of pro-inflammatory and pro-fibrotic gene expression, mediated by DNA methylation, histone modifications or microRNAs, is important in EMT and renal fibrogenesis.

DNA Methylation

DNA methylation occurs at the 50-position of the cytosine ring (5mC) within CpG dinucleotides of gene promotors. It is catalyzed by DNA methyltransferases (DNMTs). By inhibiting access of transcription factors to the binding sites or promoting the recruitment of methyl-binding domain proteins, gene expression is changed.

found altered transcription of EMT-related genes in accordance with the dynamic changes of DNA methylation, reinforcing the role of the epigenetic mechanisms in the development of EMT. Direct methylation of certain transcription factors such as KLF4 and RASAL1 by Dnmt1 contributes to the progression of EMT in renal epithelial cells and is associated with fibrogenesis in the kidneys. In arsenic-induced renal fibrosis, treatment with a DNA methylation inhibitor reversed the EMT properties of HK-2 cells, suggesting that the fibrotic changes are mediated by DNA methylation. There is still debate over the role of DNA methylation in renal fibrosis and EMT. By using comprehensive high-throughput arrays for relative methylation and TGF-β stimulation during EMT in AML12 cells, showed no changes in DNA methylation.

Histone Modification

Histone modification may be a key determinant of progression in renal diseases. The histone octamer is composed of a H3-H4 tetramer and two separate H2A-H2B dimers. The modifications, including acetylation, methylation, phosphorylation, ubiquitination, have been proposed to constitute specific biological outcomes.

Recent studies show that histone acetylation through histone deacetylases (HDACs) activation mediated several physiological and pathophysiological changes in the kidney. Inhibition of histone deacetylase activity attenuated renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Histone 3 lysine 4 acetylation (H3K4Ac) is observed in the promoter regions of EMT marker genes, such as CDH1 and VIM. In hypoxia-induced EMT, HIF-1α induced histone deacetylase and then regulated EMT related gene expression. investigated epigenetic modifications during EMT mediated by TGF-β, they found a reduction in the heterochromatin marker H3 Lys9 dimethylation (H3K9Me2), an increase in the euchromatin marker H3 Lys4 trimethylation (H3K4Me3) and in the transcriptional mark H3 Lys36 trimethylation (H3K36Me3). This suggests that during the process of EMT, specific chromatin domains across the genome were reprogrammed. In the UUO model, the number of individual histone markers, H3K9 acetylation (H3K9Ac) and tri-methylation (H3K9Me3) in proximal tubules and myofibroblasts, was increased 10 days after UUO. Targeting methyltransferases, such as disruptor of telomeric silencing-1 like (DOT1L) and enhancer of zeste homolog 2 (EZH2), attenuates EMT and fibroblast activation by suppressing activation of multiple profibrotic signaling pathways. So, regulation of histone modification could be a strategy to interfere with the EMT process.

MicroRNA

MicroRNA (miRNAs) are small, non-coding nucleotides that regulate diverse biological processes including aggressiveness of cancers and fibrosis. Altered microRNA biosynthesis or regulation contributes to pathological processes including kidney fibrosis. Some suggests that microRNA crosstalk may influence epithelial-to-mesenchymal, endothelial-to-mesenchymal, and macrophage-to-mesenchymal transitions in the kidney.

Increasing evidence confirms various microRNAs are involved in the EMT process. found that after exposure to cyclosporine A (CsA), 46 miRNAs were significantly altered in proximal tubular epithelial cells, with alterations in EMT markers including vimentin and a-SMA. Several miRNAs are thought to be able to regulate different transcription factors including Snail, bHLH, and ZEB families are drivers of the epithelial plasticity leading to EMT. The miR-200 family targets two important transcriptional repressors of the cell adherence (E-cadherin) and cell polarity genes, the ZEB1 and ZEB2. The hypermethylated or unmethylated status of miR-200 can be shifted corresponding to the EMT and MET (mesenchymal–epithelial transition) phenotypes of cells. Overexpression of miR-141 in HK-2 cells blocked the process of EMT by increasing E-cadherin and decreasing vimentin and FSP1 expression. And ZEB2 and cadherin-2 were directly regulated by miR-192 and -194.

There are also some results suggesting a renal protective role of miRNA in renal injury. found that miR-30c inhibited EMT through Snail1-TGF-β1 pathway, and attenuated diabetic nephropathy. In another study, researchers found that miR-152 overexpression inhibited TGF-β1-induced EMT in HK-2 cells. It is hard to identify which miRNA determines EMT initiation, and some have suggested unbalanced control of several miRNAs.

Role of Extracellular Vesical Communication in the Kidney Injury, Recovery, and Fibrosis

Extracellular vesicles (EVs) such as exosomes are important mediators of cell-cell communication that act by transmitting proteins and genetic information. Vesicles incorporate molecules from their origin cells containing proteins, nucleic acids and lipids. A recent study demonstrated that exosomes are produced in renal proximal tubular epithelium following various fibrotic injury (UUO, ischemia/reperfusion or 5/6 nephrectomy). Stimulation of cultured renal epithelial cells with TGF-β1 also increased exosome production, and the exosome purified from these cells are able to induce renal interstitial fibroblast activation. Conversely, pharmacologic inhibition of exosome secretion or depletion of exosome from the conditioned media blocked the ability of TGF-β1 stimulated renal epithelial cells to induce renal fibroblast activation; injection of tubular cell-derived exosomes also enhanced kidney injury and fibrosis. Given that TGF-β1 is a potent inducer of partial EMT and all three fibrotic injuries cited by can induce EMT, these results suggest that tubule-derived exosomes play an essential role in driving renal fibroblast activation and fibrogenesis. Since tubule-derived exosomes contain numerous miRNAs and growth factors that are beneficial to renal recovery and repair, TECs may also employ exosomes to regulate renal reparative responses. In addition, tubular-derived EVs may regulate inflammatory responses to affect renal injury, fibrosis and repair. In this regard, it has been reported that tail-vein injection of DM mice with EVs from HSA-induced HK-2 cells induces kidney macrophage M1 polarization and accelerate the progression of diabetic kidney disease through miR-199a-5p. Currently, there is still no direct evidence indicating whether renal epithelial cells undergoing EMT would promote EVs production and release. It has been reported that slug-mediated partial EMT in hepatocellular carcinoma cells can promote exosomal secretion of some proteins that can be considered as potential non-invasive biomarkers. Based on the importance of tubular-derived EVs in regulating cellular communication and functional responses, it will be interesting to further elucidate the role and mechanism of extracellular vesicles in inducing partial EMT development and in mediating partial EMT regulated kidney injury and repair. Several recent review articles have described the production, regulation and therapeutic implication of extracellular vesicles in the kidney after acute and chronic injuries.

Conclusion

Kidney fibrosis is a multi-factorial and multi-cellular disease. All cell types present in the kidney including epithelial cells, endothelial cells, mesangial cells, as well as immune cells contribute to the progression of chronic kidney diseases. EMT has long been recognized as a main mechanism mediating renal interstitial fibrosis. In recent years, the proposal of partial EMT sets a novel insight on generation of epithelium dysfunction and tubulointerstitial fibrosis. According to recent studies, epithelial cell undergoes cell cycle arrest and metabolic alternation, inducing the infiltration of immune cells and disturbed epithelial-mesenchymal crosstalk, initiating and accelerating the process of fibrogenesis (Figure 1). Main findings related to partial EMT were listed in Table 1. More recent evidence demonstrates a role for epigenetic regulation of EMT. Considerable work still needs to be done to achieve more therapeutic possibilities.

Author Contributions

LS wrote the manuscript. SZ edited the manuscript. Both authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 110

  1. 1.

    Abbate M. Zoja C. Rottoli D. Corna D. Tomasoni S. Remuzzi G. (2002 ). Proximal tubular cells promote fibrogenesis by TGF-beta1-mediated induction of peritubular myofibroblasts. Kidney Int. 61 2066–2077.

    Not in our library10.1046/j.1523-1755.2002.00380.x

  2. 2.

    Bai Y. Lu H. Lin C. Xu Y. Hu D. Liang Y. (2016 ). Sonic hedgehog-mediated epithelial-mesenchymal transition in renal tubulointerstitial fibrosis. Int. J. Mol. Med. 37 1317–1327.

    Not in our library10.3892/ijmm.2016.2546

  3. 3.

    Bai Y. Lu H. Wu C. Liang Y. Wang S. Lin C. (2014 ). Resveratrol inhibits epithelial-mesenchymal transition and renal fibrosis by antagonizing the hedgehog signaling pathway. Bioche. Pharmacol. 92 484–493.

    Not in our library10.1016/j.bcp.2014.09.002

  4. 4.

    Bechtel W. McGoohan S. Zeisberg E. M. Müller G. A. Kalbacher H. Salant D. J. (2010 ). Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat. Med. 16 544–550.

    Not in our library10.1038/nm.2135

  5. 5.

    Bielesz B. Sirin Y. Si H. Niranjan T. Gruenwald A. Ahn S. (2010 ). Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J. Clin. Invest. 120 4040–4054.

    Not in our library10.1172/jci43025

  6. 6.

    Bonventre J. V. (2014 ). Primary proximal tubule injury leads to epithelial cell cycle arrest, fibrosis, vascular rarefaction, and glomerulosclerosis. Kidney Int. Suppl. (2011) 4 39–44.

    Not in our library10.1038/kisup.2014.8

  7. 7.

    Borges F. Melo S. Ozdemir B. Kato N. Revuelta I. Miller C. A. (2013 ). TGF-β1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J. Am. Soc. Nephrol. 24 385–392.

    Not in our library10.1681/asn.2012101031

  8. 8.

    Canaud G. Bonventre J. V. (2015 ). Cell cycle arrest and the evolution of chronic kidney disease from acute kidney injury. Nephrol. Dial Transpl. 30 575–583.

    Not in our library10.1093/ndt/gfu230

  9. 9.

    Carew R. M. Wang B. Kantharidis P. (2012 ). The role of EMT in renal fibrosis. Cell Tissue Res. 347 103–116.

    Not in our library10.1007/s00441-011-1227-1

  10. 10.

    Carmona F. J. Davalos V. Vidal E. Gomez A. Heyn H. Hashimoto Y. (2014 ). A comprehensive DNA methylation profile of epithelial-to-mesenchymal transition. Cancer Res. 74 5608–5619.

    Not in our library10.1158/0008-5472.can-13-3659

  11. 11.

    Chakraborty P. K. Scharner B. Jurasovic J. Messner B. Bernhard D. Thévenod F. (2010 ). Chronic cadmium exposure induces transcriptional activation of the Wnt pathway and upregulation of epithelial-to-mesenchymal transition markers in mouse kidney. Toxicol. Lett. 198 69–76.

    Not in our library10.1016/j.toxlet.2010.05.007

  12. 12.

    Chang Y. Singh K. P. (2019 ). Arsenic induces fibrogenic changes in human kidney epithelial cells potentially through epigenetic alterations in DNA methylation. J. Cell Physiol. 234 4713–4725.

    Not in our library10.1002/jcp.27244

  13. 13.

    Chen J. Zmijewska A. Zhi D. Mannon R. B. (2015 ). Cyclosporine-mediated allograft fibrosis is associated with micro-RNA-21 through AKT signaling. Transpl. Int. 28 232–245.

    Not in our library10.1111/tri.12471

  14. 14.

    Cianciolo C. C. Skrypnyk N. I. Brilli L. L. Chiba T. Novitskaya T. Woods C. (2013 ). Histone deacetylase inhibitor enhances recovery after AKI. J. Am. Soc. Nephrol. 24 943–953.

    Not in our library10.1681/asn.2012111055

  15. 15.

    Davalos V. Moutinho C. Villanueva A. Boque R. Silva P. Carneiro F. (2012 ). Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 31 2062–2074.

    Not in our library10.1038/onc.2011.383

  16. 16.

    De Chiara L. Crean J. (2016 ). Emerging transcriptional mechanisms in the regulation of epithelial to mesenchymal transition and cellular plasticity in the kidney. J. Clin. Med. 5:6.

    Not in our library10.3390/jcm5010006

  17. 17.

    Díaz-López A. Díaz-Martín J. Moreno-Bueno G. Cuevas E. P. Santos V. Olmeda D. (2015 ). Zeb1 and Snail1 engage miR-200f transcriptional and epigenetic regulation during EMT. Inter J. Cancer 136 E62–E73.

    Not in our library10.1002/ijc.29177

  18. 18.

    Ding H. Zhou D. Hao S. Zhou L. He W. Nie J. (2012 ). Sonic hedgehog signaling mediates epithelial-mesenchymal communication and promotes renal fibrosis. J. Am. Soc. Nephrol. 23 801–813.

    Not in our library10.1681/asn.2011060614

  19. 19.

    Djudjaj S. Boor P. (2018 ). Cellular and molecular mechanisms of kidney fibrosis. Mol. Aspects Med. 65 16–36.

    Not in our library10.1016/j.mam.2018.06.002

  20. 20.

    Docherty M. H. O’Sullivan E. D. Bonventre J. V. Ferenbach D. A. (2019 ). Cellular senescence in the kidney. J. Am. Soc. Nephrol. 30 726–736.

    Not in our library10.1681/asn.2018121251

  21. 21.

    Eddy A. A. Neilson E. G. (2006 ). Chronic kidney disease progression. J. Am. Soc. Nephrol. 17 2964–2966.

    Not in our library10.1681/asn.2006070704

  22. 22.

    Erdbrügger U. Le T. H. (2016 ). Extracellular vesicles in renal diseases: more than novel biomarkers? J. Am. Soc. Nephrol. 27 12–26.

    Not in our library10.1681/asn.2015010074

  23. 23.

    Farris A. B. Colvin R. B. (2012 ). Renal interstitial fibrosis. Curr. Opin. Nephrol. Hypertens. 21 289–300.

    Not in our library10.1097/mnh.0b013e3283521cfa

  24. 24.

    Fine L. G. Ong A. C. Norman J. T. (1993 ). Mechanisms of tubulo-interstitial injury in progressive renal diseases. Eur. J. Clin. Invest. 23 259–265.

    Not in our library10.1111/j.1365-2362.1993.tb00771.x

  25. 25.

    Fragiadaki M. Mason R. M. (2011 ). Epithelial−mesenchymal transition in renal fibrosis – evidence for and against. Int. J. Exp. Pathol. 92 143–150.

    Not in our library10.1111/j.1365-2613.2011.00775.x

  26. 26.

    Gonzalez D. M. Medici D. (2014 ). Signaling mechanisms of the epithelial-mesenchymal transition. Sci. Signal. 7:e8.

    Not in our library10.1126/scisignal.2005189

  27. 27.

    Grande M. T. Sánchez-Laorden B. López-Blau C. De Frutos C. A. Boutet A. Arévalo M. (2015 ). Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat. Med. 21 989–997.

    Not in our library10.1038/nm.3901

  28. 28.

    Guan H. Peng R. Mao L. Fang F. Xu B. Chen M. (2020 ). Injured tubular epithelial cells activate fibroblasts to promote kidney fibrosis through miR-150-containing exosomes. Exp. Cell Res. 392:112007.

    Not in our library10.1016/j.yexcr.2020.112007

  29. 29.
  30. 30.

    Hajarnis S. Yheskel M. Williams D. Brefort T. Glaudemans B. Debaix H. (2018 ). Suppression of microRNA activity in kidney collecting ducts induces partial loss of epithelial phenotype and renal fibrosis. J. Am. Soc. Nephrol. 29 518–531.

    Not in our library10.1681/asn.2017030334

  31. 31.

    Hertig A. Anglicheau D. Verine J. Pallet N. Touzot M. Ancel PY. (2008 ). Early epithelial phenotypic changes predict graft fibrosis. J. Am. Soc. Nephrol. 19 1584–1591.

    Not in our library10.1681/asn.2007101160

  32. 32.

    Hewitson T. D. Holt S. G. Tan S. Wigg B. Samuel C. S. Smith ER. (2017 ). Epigenetic modifications to H3K9 in renal tubulointerstitial cells after unilateral ureteric obstruction and TGF-β1 stimulation. Front. Pharmacol. 8:307.

    Not in our library10.3389/fphar.2017.00307

  33. 33.

    Huang Y. Tong J. He F. Yu X. Fan L. Hu J. (2015 ). MiR-141 regulates TGF-beta1-induced epithelial-mesenchymal transition through repression of HIPK2 expression in renal tubular epithelial cells. Int. J. Mol. Med. 35 311–318.

    Not in our library10.3892/ijmm.2014.2008

  34. 34.

    Humphreys B. D. Lin S. Kobayashi A. Hudson T. E. Nowlin B. T. Bonventre JV. (2010 ). Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176 85–97.

    Not in our library10.2353/ajpath.2010.090517

  35. 35.

    Irifuku T. Doi S. Sasaki K. Doi T. Nakashima A. Ueno T. (2016 ). Inhibition of H3K9 histone methyltransferase G9a attenuates renal fibrosis and retains klotho expression. Kidney Int. 89 147–157.

    Not in our library10.1038/ki.2015.291

  36. 36.

    Iwano M. Plieth D. Danoff T. M. Xue C. Okada H. Neilson EG. (2002 ). Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 110 341–350.

    Not in our library10.1172/jci15518

  37. 37.

    Jenkins R. H. Davies L. C. Taylor P. R. Akiyama H. Cumbes B. Beltrami C. (2014 ). MiR-192 induces G2/M growth arrest in aristolochic acid nephropathy. Am. J. Pathol. 184 996–1009.

    Not in our library10.1016/j.ajpath.2013.12.028

  38. 38.

    Jia Y. Zheng Z. Xue M. Zhang S. Hu F. Li Y. (2019 ). Extracellular vesicles from albumin-induced tubular epithelial cells promote the M1 macrophage phenotype by targeting klotho. Mol. Ther. 27 1452–1466.

    Not in our library10.1016/j.ymthe.2019.05.019

  39. 39.

    Johnson D. W. Saunders H. J. Baxter R. C. Field M. J. Pollock C. A. (1998 ). Paracrine stimulation of human renal fibroblasts by proximal tubule cells. Kidney Int. 54 747–757.

    Not in our library10.1046/j.1523-1755.1998.00048.x

  40. 40.

    Kaissling B. LeHir M. Kriz W. (2013 ). Renal epithelial injury and fibrosis. Biochim. Biophys. Acta (BBA) 1832 931–939.

    Not in our library10.1016/j.bbadis.2013.02.010

All 110 references

Cited by papers we hold 7

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.